Huang Rongmei, He Yinan
Department of Obstetrics and Gynecology, Ya'an People's Hospital, Ya'an, 625000, China.
Pediatric Intensive Care Unit, Ya'an People's Hospital, Ya'an, 625000, China.
BMC Womens Health. 2025 Jun 6;25(1):282. doi: 10.1186/s12905-025-03787-z.
This study aims to investigate the effectiveness and safety of the combination of liraglutide and metformin for clinical treatment of patients with polycystic ovary syndrome.
Computerized searches were performed on PubMed, Embase, Web of Science, The Cochrane Library, CNKI, CBM, Wanfang, and VIP databases to collect randomized controlled trials(RCT) on the efficacy of metformin and liraglutide in the treatment of polycystic ovary syndrome. The search period spanned from the inception of the databases to August 2024. Following literature screening, data extraction, and risk of bias assessment in the included studies, two reviewers independently conducted meta-analysis using RevMan 5.4 software.
A total of 12 RCT involving 1096 patients were analyzed. The meta-analysis revealed that the group receiving metformin combined with liraglutide demonstrated superiority over the group receiving metformin alone in terms of body mass index (BMI), glucose levels, lipid levels, hormone levels, establishment of menstrual cycles, normal ovulation rate, and rate of spontaneous conception. However, the former group also exhibited a higher incidence of gastrointestinal reactions compared to the latter group.
Current data indicates that the combination of liraglutide and metformin can effectively enhance glucose and lipid metabolism in Polycystic Ovary Syndrome infertility patients. Additionally, it can reduce serum sex hormone levels, leading to significant clinical therapeutic effects. This treatment also improves pancreatic islet and ovarian function, ultimately increasing the rate of ovulation and pregnancy. It is important to note that correct administration methods must be followed to minimize adverse reactions.
本研究旨在探讨利拉鲁肽与二甲双胍联合应用于多囊卵巢综合征患者临床治疗的有效性和安全性。
通过计算机检索PubMed、Embase、Web of Science、Cochrane图书馆、中国知网（CNKI）、中国生物医学文献数据库（CBM）、万方数据库和维普数据库，收集二甲双胍和利拉鲁肽治疗多囊卵巢综合征疗效的随机对照试验（RCT）。检索时间跨度为各数据库建库至2024年8月。在对纳入研究进行文献筛选、数据提取和偏倚风险评估后，两名评价员独立使用RevMan 5.4软件进行荟萃分析。
共分析了12项涉及1096例患者的RCT。荟萃分析显示，在体重指数（BMI）、血糖水平、血脂水平、激素水平、月经周期建立、正常排卵率和自然受孕率方面，接受二甲双胍联合利拉鲁肽治疗的组优于单独接受二甲双胍治疗的组。然而，与后一组相比，前一组胃肠道反应的发生率也更高。
目前的数据表明，利拉鲁肽与二甲双胍联合应用可有效改善多囊卵巢综合征不孕患者的糖脂代谢。此外，它还能降低血清性激素水平，产生显著的临床治疗效果。这种治疗方法还能改善胰岛和卵巢功能，最终提高排卵率和妊娠率。需要注意的是，必须遵循正确的给药方法以尽量减少不良反应。
